In addition, work from various groups confirmed SLFN11 as being a determinant of sensitivity to a broad range of DDAs with different modes of action (1–6, 54), as well as PARP inhibitors (6–9), in different, mainly preclinical, cancer settings. The gene discussed is PARP1; the disease is cancer.